How by bowing down to short-sighted patient interest pressures the NHS may be harming others:
Funding the drug would mean 355 patients not receiving post-surgery treatment – 16 of whom would be cured, or around 200 patients not receiving palliative chemotherapy.
The researchers say there is little long-term data on the clinical benefits and potential dangers of taking Herceptin, whereas the established treatments have been shown to be clinically and cost effective.
